WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/047701    International Application No.:    PCT/JP2012/074968
Publication Date: 04.04.2013 International Filing Date: 27.09.2012
C07D 205/04 (2006.01), A61K 31/397 (2006.01), A61K 31/40 (2006.01), A61K 31/445 (2006.01), A61K 31/4523 (2006.01), A61K 31/453 (2006.01), A61K 31/454 (2006.01), A61K 31/4545 (2006.01), A61K 31/5377 (2006.01), A61P 9/00 (2006.01), A61P 9/06 (2006.01), A61P 9/10 (2006.01), A61P 9/12 (2006.01), A61P 9/14 (2006.01), A61P 11/00 (2006.01), A61P 25/00 (2006.01), A61P 43/00 (2006.01), C07D 207/10 (2006.01), C07D 207/12 (2006.01), C07D 211/48 (2006.01), C07D 401/12 (2006.01), C07D 405/12 (2006.01)
Applicants: ONO PHARMACEUTICAL CO., LTD. [JP/JP]; 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 5418526 (JP)
Inventors: NAGANAWA, Atsushi; (JP).
KUSUMI, Kensuke; (JP).
OTSUKI, Kazuhiro; (JP).
SEKIGUCHI, Tetsuya; (JP).
KAKUUCHI, Akito; (JP).
YAMAMOTO, Hiroshi; (JP).
NONAKA, Shigeyuki; (JP)
Agent: AOKI, Atsushi; SEIWA PATENT & LAW, Toranomon 37 Mori Bldg., 5-1, Toranomon 3-chome, Minato-ku, Tokyo 1058423 (JP)
Priority Data:
2011-213987 29.09.2011 JP
(JA) フェニル誘導体
Abstract: front page image
(EN)A compound represented by general formula (I-1) (where all of the symbols are as defined in the specification) has a powerful human S1P2 antagonist action as a result of the introduction of two cyclic groups, particularly phenoxy groups, at predetermined substitution positions of said compound. It is therefore possible to obtain a therapeutic agent for S1P2-mediated disease, such as vasoconstriction-related disease, fibrosis, respiratory disease, and the like.
(FR)La présente invention concerne un composé représenté par la formule générale (I-1) (où tous les symboles sont tels que définis dans la description), qui a une action antagoniste du S1P2 humain puissante comme résultat de l'introduction de deux groupes cycliques, en particulier des groupes phénoxy, à des positions de substitution prédéterminées dudit composé. Il est donc possible d'obtenir un agent thérapeutique pour une maladie à médiation par S1P2, telle qu'une maladie se rapportant à une vasoconstriction, une fibrose, une maladie respiratoire et similaires.
(JA) 一般式(I-1)(式中、すべての記号は明細書記載の通り。)で示される化合物は、2つの環状基、特にフェノキシ基を特定の置換位置に導入することによって、強力なヒトS1P拮抗活性を有することから、S1P介在性疾患、例えば、血管の収縮に起因する疾患、線維症、呼吸器系疾患等の治療剤となり得る。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)